Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Guidelines

Diagnosis and Treatment

• The American College of Physicians recommends initiating complement inhibitors (eculizumab or ravulizumab) immediately upon suspicion of aHUS, without waiting for genetic test results, as genetic mutations are only identified in 50-60% of cases 1, 2
• The Centers for Disease Control and Prevention (CDC) suggests that aHUS is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment, with a classic triad of anemia, thrombocytopenia, and renal failure 1

Diagnostic Tests

• The National Institute of Diabetes and Digestive and Kidney Diseases recommends the following diagnostic tests: ADAMTS13 activity to exclude thrombotic thrombocytopenic purpura (TTP), Shiga toxin/E. coli O157 testing to exclude STEC-HUS, complement tests (C3, C4, CH50, and anti-complement antibodies), and a complete blood count with peripheral smear showing >1% schizocytes 1, 2

Treatment and Management

• The European Medicines Agency recommends that eculizumab treatment should be administered for at least 6 months 2
• The American Society of Nephrology suggests that platelet transfusions should be avoided unless there is life-threatening bleeding, as they can worsen microangiopathic thrombosis 1, 2
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that patients with aHUS should be monitored for signs of recurrence, including clinical presentation, laboratory data, and proteinuria 1

Special Considerations

• The International Society of Nephrology recommends that genetic testing, including next-generation sequencing of genes such as CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, and CFB, should be performed in patients with aHUS 3
• The European Society of Pediatric Nephrology suggests that patients with aHUS should have access to genetic counseling once the diagnosis is confirmed 3, 1

Critical Pitfalls to Avoid

• The American College of Physicians recommends that treatment with eculizumab should not be delayed while waiting for genetic test results if aHUS is suspected and STEC-HUS is excluded 1, 2
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that platelet transfusions should not be administered in aHUS, as they can worsen microangiopathic thrombosis 1, 2

Management of Atypical Hemolytic Uremic Syndrome

Critical First Steps

• Obtain urgent hematology consultation as delay in identification is associated with increased mortality and morbidity, according to the American Society of Clinical Oncology 4, 5
• Transfuse red blood cells only for symptomatic anemia or to achieve hemoglobin 7-8 g/dL in stable patients, as recommended by the American Society of Clinical Oncology 4, 5
• Transfuse minimum number of RBC units necessary to relieve symptoms, as suggested by the American Society of Clinical Oncology 4, 5
• Provide folic acid 1 mg daily supplementation, as recommended by the American Society of Clinical Oncology 4, 5

Diagnostic Testing

• Measure LDH, haptoglobin, indirect bilirubin, and reticulocyte count to confirm hemolysis, as part of the diagnostic workup for atypical HUS, according to Pharmacological Research 6, 7

Special Considerations

• The American Society of Clinical Oncology recommends discussing with blood bank team before any transfusions that patient has possible complement-mediated TMA 4, 5
• Genetic testing, including next-generation sequencing of complement genes, should be ordered after treatment initiation, as recommended by Pharmacological Research 6, 7
• Provide genetic counseling once diagnosis confirmed due to possible genetic transmission, as suggested by Pharmacological Research 6, 7

First‑Line Treatment and Management of Atypical Hemolytic Uremic Syndrome (aHUS)

Initiation of Complement Inhibition

• Initiate eculizumab (or ravulizumab) within 4–8 hours of clinical diagnosis of aHUS; treatment delays are associated with increased morbidity and mortality. 8
• Eculizumab and ravulizumab have equivalent efficacy; ravulizumab provides a longer duration of effect and allows less frequent infusions, which may improve convenience. 8

Vaccination and Antimicrobial Prophylaxis

• Administer both quadrivalent meningococcal conjugate vaccine (serogroups A, C, W, Y) and meningococcal B vaccine at least 2 weeks before starting complement inhibition (or immediately if therapy cannot be delayed). 8
• Provide continuous antimicrobial prophylaxis with penicillin (or a macrolide if penicillin‑allergic) for the entire period of eculizumab or ravulizumab therapy. 8

Laboratory and Clinical Monitoring

• Perform serum creatinine measurement and urinalysis for hematuria/proteinuria regularly to detect renal involvement and disease activity. 8
• Target a platelet count > 150 000 /mm³ (or avoid a reduction > 25 % from baseline) as a marker of hematologic response. 8
• Continuously monitor patients for signs and symptoms of meningococcal infection throughout complement inhibitor treatment. 8

Discontinuation Considerations

• Use genetic risk stratification to guide decisions about stopping complement inhibition; the absence of identified complement‑gene mutations does not guarantee low recurrence risk. 8

Management of Atypical Hemolytic Uremic Syndrome (aHUS)

Immediate Complement Inhibition

• Initiate complement inhibition with eculizumab or ravulizumab within 4–8 hours of clinical diagnosis of aHUS; treatment must not be delayed while awaiting genetic test results. 9

Choice of Complement Inhibitor

• Eculizumab and ravulizumab demonstrate equivalent efficacy for aHUS; ravulizumab offers a longer dosing interval (every 8 weeks versus every 2 weeks for eculizumab). 9

Genetic Considerations

• Approximately 40–50 % of patients with aHUS have no detectable pathogenic mutation in complement‑regulatory genes; therefore, a negative genetic panel does not exclude the diagnosis. [9][10]
• After therapy has begun, obtain next‑generation sequencing of complement‑related genes (e.g., CFH, CFI, CD46, C3, CFB, etc.) to inform long‑term management and family screening, but do not let results postpone treatment. 9

Supportive Care Measures (identical to typical HUS)

• Provide meticulous fluid and electrolyte management to preserve renal function. [11][12]
• Initiate renal replacement therapy (dialysis) when indicated for severe uremia, hyper‑kalemia, volume overload, or acidosis. 11
• Maintain aggressive blood‑pressure control to prevent hypertensive complications. 11

Monitoring and Relapse Surveillance

• During the acute phase, perform daily laboratory assessments (hemoglobin, platelet count > 150 000/mm³, LDH, creatinine, electrolytes) to gauge response to complement inhibition.
• Continuously watch for meningococcal infection signs (fever, headache, neck stiffness, rash) throughout therapy.
• For relapse detection, monitor clinical status together with hemolysis markers, proteinuria, and microscopic hematuria. 9

Discontinuation Risks

• Stopping eculizumab carries a 10–20 % risk of disease recurrence, which may lead to acute renal failure. 9

Multidisciplinary Team Requirements

• aHUS management requires a coordinated team comprising a nephrologist (lead), hematologist, emergency physician, intensivist, neurologist, pediatrician (for children), and psychologist. [11][12]

Special Population – Pregnancy‑Associated aHUS

• Pregnancy can trigger aHUS in individuals with underlying genetic susceptibility; urgent eculizumab therapy is indicated when acute TMA with the full clinical triad appears during gestation. [11][9]